BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36726941)

  • 1. bpMRI and mpMRI for detecting prostate cancer: A retrospective cohort study.
    Pan Y; Shen C; Chen X; Cao D; Jiang J; Xu W; Ji C; Pan X; Zheng B
    Front Surg; 2022; 9():1096387. PubMed ID: 36726941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
    Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
    Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
    Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH
    AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189
    [No Abstract]   [Full Text] [Related]  

  • 4. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
    Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
    Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
    Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
    World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis.
    Feng X; Chen X; Peng P; Zhou H; Hong Y; Zhu C; Lu L; Xie S; Zhang S; Long L
    BMC Urol; 2024 Feb; 24(1):40. PubMed ID: 38365673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
    J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI.
    Liang L; Qi F; Cheng Y; Zhang L; Cao D; Cheng G; Hua L
    Sci Rep; 2021 Mar; 11(1):6048. PubMed ID: 33723287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI.
    Chen T; Zhang Z; Tan S; Zhang Y; Wei C; Wang S; Zhao W; Qian X; Zhou Z; Shen J; Dai Y; Hu J
    Front Oncol; 2021; 11():792456. PubMed ID: 35127499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic performance in clinically significant prostate cancer with PI-RADS version 2.1: simplified bpMRI versus standard mpMRI.
    Song J; Zhao C; Zhang F; Yuan Y; Wang LM; Sah V; Zhang J; Weng W; Yang Z; Wang Z; Wang L
    Abdom Radiol (NY); 2023 Feb; 48(2):704-712. PubMed ID: 36464756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
    Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies.
    Knaapila J; Jambor I; Ettala O; Taimen P; Verho J; Perez IM; Kiviniemi A; Pahikkala T; Merisaari H; Lamminen T; Saunavaara J; Aronen HJ; Syvänen KT; Boström PJ
    Eur Urol Focus; 2021 May; 7(3):522-531. PubMed ID: 32418878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic magnetic resonance imaging for primary prostate cancer evaluation: Diagnostic potential of a non-contrast-enhanced bi-parametric approach enhanced with relaxometry measurements.
    Arita Y; Akita H; Fujiwara H; Hashimoto M; Shigeta K; Kwee TC; Yoshida S; Kosaka T; Okuda S; Oya M; Jinzaki M
    Eur J Radiol Open; 2022; 9():100403. PubMed ID: 35242886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factor analysis and optimal cutoff value selection of PSAD for diagnosing clinically significant prostate cancer in patients with negative mpMRI: results from a high-volume center in Southeast China.
    Lin S; Jiang W; Ding J; Hao S; Chen H; Xie L; Zheng X
    World J Surg Oncol; 2024 May; 22(1):140. PubMed ID: 38802859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified Predictive Model and Nomogram by Incorporating Prebiopsy Biparametric Magnetic Resonance Imaging With Clinical Indicators for Prostate Biopsy Decision Making.
    Pan JF; Su R; Cao JZ; Zhao ZY; Ren DW; Ye SZ; Huang RD; Tao ZL; Yu CL; Jiang JH; Ma Q
    Front Oncol; 2021; 11():740868. PubMed ID: 34589437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
    Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
    Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study.
    Brembilla G; Giganti F; Sidhu H; Imbriaco M; Mallett S; Stabile A; Freeman A; Ahmed HU; Moore C; Emberton M; Punwani S
    Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING).
    Wetterauer C; Matthias M; Pueschel H; Deckart A; Bubendorf L; Mortezavi A; Arbelaez E; Jean Winkel D; Heye T; Boll DT; Merkle E; Hayoz S; Seifert HH; Rentsch CA
    Eur Urol Focus; 2024 Feb; ():. PubMed ID: 38402105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Creating a novel multiparametric magnetic resonance imaging-based biopsy strategy for reducing unnecessary prostate biopsies: a retrospective cohort study.
    Wang C; Shen D; Yuan L; Dong Q; Xu S; Liu Y; Xiao J
    Quant Imaging Med Surg; 2024 Feb; 14(2):2021-2033. PubMed ID: 38415121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.